arrow
S

Sara Pizzamiglio

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:29
被引数:2,612

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy

HER2-low乳腺癌是免疫冷型肿瘤:肿瘤浸润免疫细胞的见解及其对免疫治疗的启示

2025-12-030
OAAI
Data-Driven Motion Correction of 11C-Methionine PET Images on a Cohort of Pediatric Patients With Brain Tumor in a PET/MRI Study

在PET/MRI研究中对儿童脑肿瘤患者队列的 <sup>11</sup>C-蛋氨酸PET图像进行数据驱动的运动校正

2025-05-080
PRE
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial

重新定义接受新辅助化疗的高风险软组织肉瘤的放射学反应:ISG-STS 1001随机临床试验的最终结果

2025-03-010
OAAI
A gene expression-based classifier for HER2-low breast cancer
2024-02-010
OAAI
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
2022-07-0515
OA
The future of HER2-positive breast cancer patients might be written in miRNAs: An exploratory analysis from the NeoALTTO study
2022-02-150
PRE
High CD36 expression predicts worse event free survival in HER2-positive breast cancer patients treated with neoadjuvant trastuzumab-based therapy: An exploratory analysis of the NeoALTTO study
2022-02-151
PRE
Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

HER2-Positive乳腺癌的综合分子和免疫表型以及对新辅助治疗的反应: 新探索性分析

2021-12-019
OA
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study
2019-09-0115
OAAI
Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
2019-07-0140
OAAI
High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial
2018-04-0158
PREAI